AIMS: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. METHODS:16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. RESULTS:IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters. CONCLUSION:Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.
RCT Entities:
AIMS: To determine the visual outcome following initiation of brimonidine therapy in glaucoma. METHODS: 16 newly diagnosed previously untreated glaucomapatients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months. RESULTS: IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters. CONCLUSION:Glaucomapatients exhibit improved CS on initiation of brimonidine therapy.
Authors: João M Beirão; Luciana M Moreira; João C Oliveira; Maria J Menéres; Bernardete B Pessoa; Maria E Matos; Paulo P Costa; Paulo A Torres; Idalina B Beirão Journal: Mol Vis Date: 2014-07-02 Impact factor: 2.367